648TiP PSMAfore: A phase III study to compare 177Lu-PSMA-617 treatment with a change in androgen receptor pathway inhibitor in taxane-naïve patients with mCRPC
Year: 2021
Type: article
Source: Annals of Oncology
Authors: M.J. Morris, O. Sartor, K.N. Chi, J.S. de Bono, N.D. Shore, M. Crosby, D. Dalal, K. Fizazi
Language: English
Subfield: Radiology, Nuclear Medicine and Imaging
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
Funders: Amgen, Bristol-Myers Squibb, Eli Lilly and Company, Pfizer, AstraZeneca, GlaxoSmithKline, Sanofi, Celgene, Endocyte, Boston Scientific Corporation, Taiho Pharmaceutical, Astex Pharmaceuticals, Clovis Oncology, Menarini Silicon Biosystems, Constellation Pharmaceuticals, Cardinal Health, Advanced Accelerator Applications, UroGen Pharma, Invitae, Deutsche Forschungsgemeinschaft, Eisai, Astellas Pharma, Sierra Oncology, Genentech, Foundation Medicine, Daiichi Sankyo Europe
OpenAlex ID: W3202375713